PD-1 checkpoint inhibition in Leishmania infection of primary human cells
Date issued
Authors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
License
Abstract
In this study we investigated the impact of Programmed Death-1/Programmed Death-1 ligand (PD-1/PD-L) axis in an in vitro Leishmania major (Lm) infection model consisting of primary human myeloid and lymphoid cells. Two different PD-1 checkpoint inhibitors (IgG1 and IgG4) were used to modulate the PD-1/PD-L interactions in different Lm-specific T-cell assay setups. As read-outs, Lm-induced T-cell proliferation and Lm infection rate in host cells was assessed.
First, PD-1 ligand expression was demonstrated on three different Lm host cells, namely pro-inflammatory and anti-inflammatory human monocyte-derived macrophages (hMDM1 and hMDM2) and dendritic cells (hMDDC). PD-1 checkpoint blockade had no significant impact on Lm-induced T-cell proliferation or Lm infection rate in a co-culture of Lm-infected host cells together with autologous peripheral blood lymphocytes (PBLs). Using an approach with pre-cultured leucocytes (RESTORE-Assay by Römer et al. 2011) which mimics tissue-like conditions and renders T-cells more responsive to their cognate antigen, revealed a similar picture. Although PD-1 and its ligands were detectable in this assay, no significant differences in T-cell proliferation due to PD-1 checkpoint blockade were observed.
Because PD-1/PD-L interactions are highly prominent during chronic inflammation and antigen stimulation, we investigated an approach using phytohemagglutinin-pre-stimulated PBLs in a co-culture with infected hMDM1, hMDM2 or hMDDC. In this approach, two different PD-1 checkpoint inhibitors (IgG1 and IgG4) increased T-cell effector functions in a similar manner. As a consequence Lm infection decreased, being the most pronounced in hMDDC, compared to hMDM1 and hMDM2. Focusing on hMDDC, effects mediated by PD-1 blockade were shown to be partially TNFα dependent. Moreover, treatment with the therapeutic PD-1 checkpoint inhibitor nivolumab specifically enhanced proliferation of CD4+ T-cells, increased expression of the TH1-specific transcription factor Tbet, T-cell activation markers and cytolytic effector proteins, which at large might be implicated in enhanced parasite killing. In all, our data describe an important role for the PD-1/PD-L axis upon Lm infection using a human primary cell system. These data contribute to a better understanding of the PD-1/PD-L-induced T-cell impairment during infectious disease and its influence on immune effector mechanisms to combat Lm infection.